TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: <1nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 6nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 6nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 6nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 6nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 7nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 7nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 7nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 7nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 7nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 8nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 8nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 8nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 9nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 9nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 9nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 11nMAssay Description:Human recombinant PDE10A2 was expressed in Sf9 cells, using a recombinant baculovirus construct containing the full length sequence containing a 6×Hi...More data for this Ligand-Target Pair